Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →
| Demonstração de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receita total | $1.7B | $1.4B | $1.0B | $829M | $660M | $443M | $268M | $196M | $152M | $317M | $147M | $135M | $75M | $55M | $42M | $56M | $14M | $14M | $9M | $4M | $1M |
| Lucro bruto | $1.3B | $1.1B | $856M | $637M | $521M | $362M | $224M | $150M | $142M | $285M | $113M | $106M | $53M | $49M | $41M | $56M | $13M | $13M | $8M | $4M | $1M |
| Margem Bruta % | 78.2% | 78.1% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% | 78.3% | 69.8% | 88.6% | 97.4% | 99.5% | 92.8% | 97.7% | 96.2% | 93.7% | 55.5% |
| Resultado Operacional (EBIT) | $945M | $816M | $551M | $338M | $268M | $276M | $144M | ($68M) | ($69M) | $81M | ($83M) | ($27M) | ($63M) | ($80M) | ($54M) | ($20M) | ($54M) | ($58M) | ($50M) | ($28M) | ($16M) |
| % de margem operacional | 56.8% | 58.5% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.6% | 25.6% | -56.7% | -20.3% | -83.7% | -146.8% | -126.7% | -35.4% | -398.2% | -427.6% | -575.5% | -740.9% | -1587.3% |
| Resultado líquido | $413M | $317M | $444M | $282M | $202M | $403M | $129M | ($72M) | ($80M) | $63M | ($103M) | ($32M) | ($68M) | ($83M) | ($54M) | ($20M) | ($53M) | ($58M) | ($49M) | ($24M) | ($15M) |
| Margem Líquida % | 24.8% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% | -23.9% | -90.8% | -152.3% | -126.5% | -35.2% | -390.8% | -426.9% | -555.1% | -628.9% | -1502.6% |
| EBITDA | — | $573M | $657M | $452M | $316M | $279M | $148M | ($64M) | ($67M) | $83M | ($81M) | ($26M) | ($61M) | ($79M) | ($53M) | ($19M) | ($53M) | ($57M) | ($49M) | ($28M) | ($15M) |
| Lucro por ação (EPS) | $3.35 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 | $-0.67 | $-0.61 | $-0.32 | $-0.24 |
| Ações em circulação (M) | — | 124M | 129M | 134M | 141M | 147M | 141M | 144M | 144M | 139M | 128M | 127M | 123M | 113M | 111M | 103M | 94M | 87M | 80M | 74M | 63M |
Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.
Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de HALO. /companies/us/HALO
As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.
About TickerBase · Data methodology & sources · Privacy · Terms